Global Information would like to present a new market research report, "Proteomics - Technologies, Markets and Companies" by Jain Pharmabiotech.
In the first decade of the 21st century, technologies in proteomics will play a significant role in molecular diagnostics, drug discovery, and general medical practice. Currently, the most common technologies used in proteomics are: protein analysis by mass spectrometry and 2D gel electrophoresis in protein separation. Additionally, technologies in functional proteomics involve yeast two-hybrid system for studying protein-protein interactions.
Initial establishment of a proteomics platform in a industrial setting entails implementation of a series of robotic systems to enable a high-throughput approach for analysis and identification of dissimilarities observed on 2D electrophoresis gels. Currently, Proteomic technologies are being assimilated into the drug discovery process as complimentary to genomic approaches. For example, toxicoproteomics (i.e. understanding toxic events through the evaluation of protein expression) is a crucial proteomic application in preclinical drug safety. Additionally, bioinformatics is important for analyzing the large amounts of data generated from both proteomics and genomics.
Over the last few years, the number of companies involved in proteomic technologies has increased dramatically. Generally, it is complicated to estimate the markets for proteomic technologies as they are not entirely distinct but rather, they overlap with those of gene expression, genomics, drug discovery, molecular diagnostics, and high throughput screening. Research analysis shows that the largest growth will be in bioinformatics and protein biochip technologies through the year 2019.